摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

布替佐辛 | 93821-75-1

中文名称
布替佐辛
中文别名
丁替索辛;丁替佐辛
英文名称
Butinazocine
英文别名
10-but-3-ynyl-13,13-dimethyl-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-triene-1,4-diol
布替佐辛化学式
CAS
93821-75-1
化学式
C18H23NO2
mdl
——
分子量
285.4
InChiKey
YEFFVIUQXXNVGG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    456.1±45.0 °C(Predicted)
  • 密度:
    1.167±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.6
  • 重原子数:
    21
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.56
  • 拓扑面积:
    43.7
  • 氢给体数:
    2
  • 氢受体数:
    3

文献信息

  • Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
    申请人:Scaramuzzino, Giovanni
    公开号:EP1336602A1
    公开(公告)日:2003-08-20
    New pharmaceutical compounds of general formula (I): F-(X)q where q is an integer from 1 to 5, preferably 1; -F is chosen among drugs described in the text, -X is chosen among 4 groups -M, -T, -V and -Y as described in the text. The compounds of general formula (I) are nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without hypotensive side effects and for this reason they are useful for the preparation of medicines for prevention and treatment of inflammatory, ischemic, degenerative and proliferative diseases of musculoskeletal, tegumental, respiratory, gastrointestinal, genito-urinary and central nervous systems.
    通式(I)的新药物化合物:F-(X)q,其中q是1到5的整数,最好是1;-F是在文本中描述的药物中选择的,-X是在文本中描述的4个组-M,-T,-V和-Y中选择的。通式(I)的化合物是硝酸盐前药,可以在体内以受控和选择性的方式释放一氧化氮,而不会产生降压副作用,因此它们非常适用于制备用于预防和治疗肌肉骨骼,皮肤,呼吸,消化,泌尿和中枢神经系统的炎症,缺血,退行性和增生性疾病的药物。
  • Diagnostic/therapeutic agents
    申请人:Klaveness Jo
    公开号:US20050002865A1
    公开(公告)日:2005-01-06
    Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.
    可定位的诊断和/或治疗活性剂,例如超声对比剂,包括悬浮在载体液中的报告物,该报告物包含含气体或生成气体的材料,该剂能够与目标形成至少两种结合对。
  • TEST KIT FOR THE QUANTITATIVE DETERMINATION OF NARCOTIC DRUGS
    申请人:CHIRON AS
    公开号:US20150204893A1
    公开(公告)日:2015-07-23
    A test kit for the quantitative determination of narcotic drugs comprising (A) series of sealed vessels, each vessel containing a deuterium free isotopologue of a narcotic drug in exactly defined concentrations and quantities, wherein the isotopologue differs from vessel to vessel and—wherein the quantities of the isotopologue differ from vessel to vessel or are the same for all vessels; and/or (B) series of sealed vessels, each vessel containing in exactly defined concentrations and quantities the same isotopologue in quantities which differ from vessel to vessel; wherein the free isotopologues are selected from narcotic drugs; prodrugs, salts, solvates, hydrates and polymorphs and contain at least three stable isotopes selected from the group consisting of 13 C, 15 N and 18 O in the molecule with a degree of labeling of at least 95 mol-%; the use of the test kit and a method for quantitatively determining narcotic drugs.
    一种用于定量测定麻醉药物的检测试剂盒,包括(A)一系列密封容器,每个容器中含有一种去同位素麻醉药物,其浓度和数量均被精确定义,其中同位素从容器到容器不同,同位素的数量在容器到容器之间不同或对所有容器都相同;和/或(B)一系列密封容器,每个容器中含有相同的同位素,其浓度和数量被精确定义,数量在容器到容器之间不同;其中自由同位素选自麻醉药物、前药、盐、溶剂、合物和多晶形,并且在分子中至少包含三种稳定同位素,所述稳定同位素选自13C、15N和18O,其标记度至少为95摩尔%;使用该检测试剂盒和一种定量测定麻醉药物的方法。
  • Test kit for the quantitative determination of narcotic drugs
    申请人:Chiron AS
    公开号:EP2687854A1
    公开(公告)日:2014-01-22
    A test kit for the quantitative determination of narcotic drugs comprising (A) series of sealed vessels, each vessel containing a deuterium free isotopologue of a narcotic drug in exactly defined concentrations and quantities, - wherein the isotopologue differs from vessel to vessel and - wherein the quantities of the isotopologue differ from vessel to vessel or are the same for all vessels; and/or (B) series of sealed vessels, each vessel containing in exactly defined concentrations and quantities the same isotopologue in quantities which differ from vessel to vessel; - wherein the free isotopologues are selected from narcotic drugs; prodrugs, salts, solvates, hydrates and polymorphs and contain at least three stable isotopes selected from the group consisting of 13C, 15N and 18O in the molecule with a degree of labeling of at least 95 mol-%; the use of the test kit and a method for quantitatively determining narcotic drugs.
    用于定量测定麻醉药品的试剂盒,包括 (A) 一系列密封容器,每个容器装有浓度和数量完全确定的麻醉药品的无 同位素、 - 其中各容器的同位素不同,并且 - 其中同位素的数量因容器而异或所有容器相同;和/或 (B) 一系列密封容器,每个容器以完全确定的浓度和数量含有相同的同位 素,其数量因容器而异; - 其中游离的同位素选自麻醉药品;原药、盐、溶液、合物和多晶型物,以及 分子中至少含有三个稳定同位素,选自 13C、15N 和 18O 组成的组,标记度至少为 95 摩尔-%; 使用检测试剂盒和方法定量测定麻醉药品。
  • Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
    申请人:Counts David F.
    公开号:US10463611B2
    公开(公告)日:2019-11-05
    The present disclosure provides a once-daily water-soluble pharmaceutically active formulation for oral administration. In certain embodiments, the composition comprises a water-soluble pharmaceutically active organic compound incorporated into a small particulate, each particulate having a core of the water-soluble pharmaceutically active organic compound or an acceptable salt thereof in reversible association with a pharmaceutically acceptable drug-binding polymer. The core of the composition being surrounded by an insoluble water permeable membrane that is capable of delaying the dissolution of the pharmaceutically active compound therewithin and providing for extended release of the pharmaceutically active compound. In some embodiments, the formulation of the invention are designed to extend release of the pharmaceutically active organic compound for about 3 hours to about 8 hours, thereby enabling preparation of an extended release formulation for any pharmaceutically active compound with a half-life of from about 16 hours to about 21 hours.
    本公开提供了一种用于口服的每日一次溶性药用活性制剂。在某些实施方案中,该组合物包括掺入小颗粒中的溶性药用活性有机化合物,每个颗粒都有一个溶性药用活性有机化合物或其可接受盐的核心,该核心与药学上可接受的药物结合聚合物可逆结合。组合物的核心由不溶性透膜包围,该膜能够延迟其中的药用活性化合物的溶解,并延长药用活性化合物的释放时间。在某些实施方案中,本发明的制剂可将药用活性有机化合物的释放时间延长约 3 小时至约 8 小时,从而能够制备半衰期为约 16 小时至约 21 小时的任何药用活性化合物的缓释制剂。
查看更多

同类化合物

非那佐辛 酮佐辛盐酸盐 酮佐辛 莫克索兴 苄卡镇痛新 脱氧-N-苄基去甲美他佐辛 美他佐辛 环佐辛 环丙止痛胺 格各佐辛 布马佐辛 布替佐辛 尹巴索兴 各马素兴 化合物 T27086 乳酸,化合物与(2alpha,6alpha,11R*)-(1)-1,2,3,4,5,6-六氢-6,11-二甲基-3-(3-甲基丁-2-烯基)-2,6-甲桥-3-苯并氮杂环辛四烯-8-醇(1:1) N-(3-氟丙基)-N-去甲美他唑新 6-乙氧基-2,2,4-三甲基-1,2-二氢喹啉 6,11-二甲基-3-丙基-1,2,3,4,5,6-六氢-2,6-亚甲基-3-苯并吖辛因 5-乙基-2'-羟基-2(N)-(3-甲基-2-丁烯基)-9-甲基-6,7-苯并吗吩烷 3-苄基-1,2,3,4,5,6-六氢-6,11-二甲基-2,6-甲桥-3-苯并氮杂环辛四烯-8-醇 3-己基-6,11-二甲基-1,2,3,4,5,6-六氢-2,6-亚甲基-3-苯并吖辛因 3-(环戊基甲基)-1,2,3,4,5,6-六氢-6,11-二甲基-2,6-甲桥-3-苯并氮杂环辛四烯-8-醇 3-(环丙基羰基)-1,2,3,4,5,6-六氢-6,11-二甲基-2,6-甲桥-3-苯并氮杂环辛四烯-8-醇 3-(环丁基甲基)-6,11-二甲基-1,2,3,4,5,6-六氢-8-甲氧基-2,6-甲桥-3-苯并氮杂环辛四烯 2-羟基-丙酸3-(环丁基甲基)-6-乙基-1,2,3,4,5,6-六氢-11,11-二甲基-2,6-甲桥-3-苯并氮杂环辛四烯-8-基酯 2-丙烯酸,2-甲基-,聚合丁基2-丙烯酸酯,乙烯基苯,2-羟基乙基2-丙烯酸酯,甲基2-甲基-2-丙烯酸酯和噁丙环基甲基2-甲基-2-丙烯酸酯 10-氮杂三环[7.3.1.02,7]十三-2,4,6-三烯 10-(环丙基甲基)-1,13-二甲基-10-氮杂三环[7.3.1.02,7]十三-2,4,6-三烯-4-醇 1,4,5,6-四氢-8-羟基-6-苯基-2,6-甲桥-3-苯并氮杂环辛四烯-3(2H)-甲酰胺 1,2,3,4,5,6-六氢-6-乙基-3-甲基-(+-)-2,6-甲桥-3-苯并氮杂环辛四烯-8-醇 1,2,3,4,5,6-六氢-6,11-二甲基-3-(3-甲基丁-2-烯基)-2,6-甲桥-3-苯并氮杂环辛四烯-8-醇盐酸盐 1,2,3,4,5,6-六氢-6,11-二甲基-3-(2-丙炔基)-2,6-甲桥-3-苯并氮杂环辛四烯-8-醇 1,2,3,4,5,6-六氢-3-环丁基甲基-6-乙基-1-甲基-2,6-甲桥-3-苯并氮杂环辛四烯-8-醇 1,2,3,4,5,6-六氢-3-(环丙基甲基)-6,11-二甲基-8-甲氧基-2,6-甲桥-3-苯并氮杂环辛四烯 1,2,3,4,5,6-六氢-3-(氰基甲基)-6,11-二甲基-2,6-甲桥-3-苯并氮杂环辛四烯-8-醇 1,2,3,4,5,6-六氢-3-(3,3-二氯-2-丙烯基)-6-乙基-11-甲基-2,6-甲桥-3-苯并氮杂环辛四烯-8-醇 1,2,3,4,5,6-六氢-3-(3,3-二氯-2-丙烯基)-6,11-二甲基-2,6-甲桥-3-苯并氮杂环辛四烯-8-醇 (2alpha,6alpha,11R*)-1,2,3,4,5,6-六氢-6,11-二甲基-2,6-甲桥-3-苯并氮杂环辛四烯-8-醇 (2S-(2a,6a,11R)-1,2,3,4,5,6-六氢-6,11-二甲基-3-(2-丙烯基)-2,6-亚甲基-3-苯并吗吩烷-8-醇盐酸盐 (-)-布马佐辛盐酸盐 (-)-去甲美他佐辛 (-)-N-丙烯基去甲变肾上腺素 盐酸盐 (-)-5,9alpha-二乙基-2'-羟基苯并吗吩烷 (+-)-(2alpha,6alpha,11R*)-苯硫代羧酸S-(1,2,3,4,5,6-六氢-3,6,11-三甲基-2,6-甲桥-3-苯并氮杂环辛四烯-8-基)酯(E)-2-丁烯二酸盐(1:1)水合物 (+)-环佐辛 (+)-喷他佐辛 3-Cyclopentyl-6,11-dimethyl-1,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocin-8-ol (S)-3,6-Dimethyl-11-phenyl-1,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocine-8,11-diol 3-Cyclopropylmethyl-4-ethyl-6-methyl-1,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocin-8-ol